Related references
Note: Only part of the references are listed.A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention
PA Scuffham et al.
CLINICAL THERAPEUTICS (2005)
Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data
A Bagust et al.
HEALTH ECONOMICS (2005)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
P Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Age and the burden of death attributable to diabetes in the United States
SH Saydah et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2002)
UKPDS 60 - Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine
V Kothari et al.
STROKE (2002)
Revealing the cost of Type II diabetes in Europe
B Jönsson
DIABETOLOGIA (2002)
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
RJ Stevens et al.
CLINICAL SCIENCE (2001)
Representing uncertainty: The role of cost-effectiveness acceptability curves
E Fenwick et al.
HEALTH ECONOMICS (2001)
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51)
P Clarke et al.
DIABETOLOGIA (2001)
One thousand health-related quality-of-life estimates
TO Tengs et al.
MEDICAL CARE (2000)
Handling uncertainty in cost-effectiveness models
AH Briggs
PHARMACOECONOMICS (2000)
Share Paper
